Skip to main content
. 2020 Apr 28;8(1):e000349. doi: 10.1136/jitc-2019-000349

Figure 2.

Figure 2

Progression-free survival of nivolumab-treated patients stratified by changes in [18F]-fluoro-2-deoxy-D-glucose positron emission tomography/MRI parameters. Kaplan-Meier curves of progression-free survival stratified by Δdiameter (A), total lesion glycolysis (ΔTLG) (B), apparent diffusion coefficient (ΔADC)mean (C) and ΔTLG+ΔADCmean (D), with cut-off values determined by receiver operating characteristic curve analysis.